• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Menu
    • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy

    Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

    Explore Muscle

    • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.

    Explore our Science

    • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories

    We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.

    Read their Stories

    • Company
    • Leadership Team
    • Careers
    • Contact Us

    Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.

    Learn More

    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
Home Company Leadership Team Arlene Morris

Arlene Morris

Director

Arlene Morris serves as a member of our board of directors and is Chief Executive Officer of Willow Advisors, a consultancy advising biotech companies on financing, strategy, and business development. She brings extensive experience in the pharmaceutical and biotechnology industries from numerous management and board roles. Previously, she spent over a decade leading public biotechnology companies, as Chief Executive Officer of Syndax Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and prior, as President and Chief Executive Officer of Affymax, where she led the company through the development of peginesatide (Omontys®). Ms. Morris also held various management and executive positions at Clearview Projects, Coulter Pharmaceutical, Scios, and Johnson & Johnson. She is currently a member of the Board of Directors of Cogent Biosciences, Palatin Technologies, TC BioPharm and Viridian Therapeutics.

  • Meet our leadership team
  • Meet our board of directors

Footer

Edgewise Therapeutics
  • Disease Areas
  • Science & Pipeline
  • Patients & Families
  • Company
  • Investors & News

Deep knowledge of integrated 
muscle physiology

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

Explore our Science

2025 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy
  • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations
  • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts